JP2018172391A5 - - Google Patents

Download PDF

Info

Publication number
JP2018172391A5
JP2018172391A5 JP2018106308A JP2018106308A JP2018172391A5 JP 2018172391 A5 JP2018172391 A5 JP 2018172391A5 JP 2018106308 A JP2018106308 A JP 2018106308A JP 2018106308 A JP2018106308 A JP 2018106308A JP 2018172391 A5 JP2018172391 A5 JP 2018172391A5
Authority
JP
Japan
Prior art keywords
factor
peptide
protein
fab
hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018106308A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018172391A (ja
JP6800180B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018172391A publication Critical patent/JP2018172391A/ja
Publication of JP2018172391A5 publication Critical patent/JP2018172391A5/ja
Application granted granted Critical
Publication of JP6800180B2 publication Critical patent/JP6800180B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018106308A 2013-08-30 2018-06-01 抗血清アルブミンfabエフェクター部分融合コンストラクト、およびその製造方法 Active JP6800180B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130104112 2013-08-30
KR10-2013-0104112 2013-08-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016538860A Division JP6422977B2 (ja) 2013-08-30 2014-08-29 抗血清アルブミンfabエフェクター部分融合コンストラクト、およびその製造方法

Publications (3)

Publication Number Publication Date
JP2018172391A JP2018172391A (ja) 2018-11-08
JP2018172391A5 true JP2018172391A5 (enExample) 2019-02-14
JP6800180B2 JP6800180B2 (ja) 2020-12-16

Family

ID=52586989

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016538860A Active JP6422977B2 (ja) 2013-08-30 2014-08-29 抗血清アルブミンfabエフェクター部分融合コンストラクト、およびその製造方法
JP2018106308A Active JP6800180B2 (ja) 2013-08-30 2018-06-01 抗血清アルブミンfabエフェクター部分融合コンストラクト、およびその製造方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016538860A Active JP6422977B2 (ja) 2013-08-30 2014-08-29 抗血清アルブミンfabエフェクター部分融合コンストラクト、およびその製造方法

Country Status (16)

Country Link
US (2) US9879077B2 (enExample)
EP (2) EP3039038B1 (enExample)
JP (2) JP6422977B2 (enExample)
KR (2) KR101576561B1 (enExample)
CN (1) CN105899532B (enExample)
AU (1) AU2014312456B2 (enExample)
BR (1) BR112016004355A2 (enExample)
CA (1) CA2922618C (enExample)
DK (1) DK3039038T3 (enExample)
ES (1) ES2866848T3 (enExample)
MX (1) MX371328B (enExample)
PH (1) PH12016500403A1 (enExample)
PL (1) PL3039038T3 (enExample)
RU (1) RU2661087C2 (enExample)
UA (1) UA117493C2 (enExample)
WO (1) WO2015030539A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108623691B (zh) * 2017-03-17 2020-05-15 北京比洋生物技术有限公司 IgG样长效免疫融合蛋白及其应用
KR20210022004A (ko) * 2018-06-18 2021-03-02 안위타 바이오사이언시스, 인코포레이티드 항-메소텔린 작제물 및 이의 용도
EP3930687A4 (en) 2019-02-25 2023-06-07 The University of Chicago METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
KR102485892B1 (ko) * 2020-04-09 2023-01-09 주식회사 에이프릴바이오 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
KR20220044057A (ko) * 2020-09-29 2022-04-06 주식회사 에이프릴바이오 인터루킨-18 결합 단백질 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질, 및 이의 용도
JP2025520393A (ja) * 2022-06-15 2025-07-03 ユーシービー バイオファルマ エスアールエル フォリスタチン-fc融合タンパク質
KR20240048577A (ko) * 2022-10-04 2024-04-16 주식회사 에이프릴바이오 난포자극 호르몬 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
CN118393137B (zh) * 2024-07-01 2024-08-20 广东赛尔生物科技有限公司 一种肠道保护菌的检测试剂盒及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
DK1517921T3 (da) * 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
KR20120133403A (ko) * 2004-06-01 2012-12-10 도만티스 리미티드 증강된 혈청 반감기를 가지는 이특이성 융합 항체
CN101031588A (zh) * 2004-06-01 2007-09-05 多曼蒂斯有限公司 药物组合物,融合物和结合物
CA2578613A1 (en) * 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
BRPI0516577A (pt) * 2004-10-05 2008-09-16 Genentech Inc agentes terapêuticos com toxicidade diminuìda
BRPI0518762A2 (pt) * 2004-12-02 2008-12-09 Domantis Ltd fusço de droga, conjugado de droga, Ácido nucleico recombinante ou isolado, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir a fusço de droga, composiÇço farmacÊutica, mÉtodo para tratamento de um indivÍduo tendo uma doenÇa inflamatària, uso de um conjugado de droga ou fusço de droga, e, composiÇço de droga
CN101155832B (zh) * 2005-02-08 2013-02-06 一般财团法人化学及血清疗法研究所 抗体的改良方法
KR20100021627A (ko) * 2007-06-08 2010-02-25 다우 글로벌 테크놀로지스 인크. Ch1 도메인의 절단에 의한 가용성 항체 단편의 발현
ES2667729T3 (es) * 2007-09-26 2018-05-14 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
MX2010011145A (es) * 2008-04-11 2011-04-11 Merrimack Pharmaceuticals Inc Enlazadores de la albumina de suero humana y conjugados de la misma.
WO2010035012A1 (en) * 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
US8685895B2 (en) * 2008-12-05 2014-04-01 Carolyn Enever Methods for selecting protease resistant polypeptides
CN102612376A (zh) * 2009-08-06 2012-07-25 诺沃-诺迪斯克保健股份有限公司 具有延长的体内功效的生长激素
GB201005063D0 (en) * 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
BR112012007374A2 (pt) * 2009-09-30 2019-09-24 Glaxo Group Ltd composição, formulação oral, injetável, inalável ou nebulizável, e, ácido nucleico isolado ou recombinante
EP2710042A2 (en) * 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
SG11201401649VA (en) * 2011-11-11 2014-07-30 Ucb Pharma Sa Albumin binding antibodies and binding fragments thereof

Similar Documents

Publication Publication Date Title
JP2018172391A5 (enExample)
RU2016105586A (ru) Гибридная конструкция, включающая антигенсвязывающий фрагмент, специфичный к сывороточному альбумину и эффекторный компонент, и способы ее получения
JP6689329B2 (ja) 免疫グロブリンFc変異体
JP6952221B2 (ja) コイルドコイルの免疫グロブリン融合タンパク質およびその組成物
KR101200659B1 (ko) 세 말단 반응기를 갖는 비펩타이드성 중합체를 이용한 생리활성 폴리펩타이드 약물 결합체
AU2005311099B2 (en) Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY
Kontermann Strategies for extended serum half-life of protein therapeutics
Strohl Fusion proteins for half-life extension of biologics as a strategy to make biobetters
ES2623925T3 (es) Proteínas de fusión de inmunoglobulina
RU2005120239A (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ
CN106661128A (zh) 构建氨基末端免疫球蛋白融合蛋白的方法及其组合物
JP2007537992A5 (enExample)
JP2007536211A5 (enExample)
AU2023324967A1 (en) Masking polypeptides, activatable novel prodrugs and methods of use thereof
IL293078A (en) A polymer of multi-functional, multi-specific biomolecules with prolonged in vivo duration
Chang et al. Advances and challenges in developing cytokine fusion proteins as improved therapeutics
TH2201000302A (th) วิธีการใหม่สำหรับการเตรียมคอนจูเกตยาที่ออกฤทธิ์ยาวนานโดยการเตรียมตัวกลาง